ASH: As Novartis enters PNH market, AstraZeneca shows longer term effect of its latest...

cafead

Administrator
Staff member
  • cafead   Dec 11, 2023 at 10:32: AM
via The week after Novartis secured a foothold in the paroxysmal nocturnal hemoglobinuria (PNH) market, AstraZeneca has released new data from its own attempt to find fresh ways of tackling this rare blood disease.

article source